Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Liabilities: 2022-2024

Historic Total Liabilities for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $36.3 million.

  • Corvus Pharmaceuticals' Total Liabilities fell 81.24% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 81.24%. This contributed to the annual value of $36.3 million for FY2024, which is 429.03% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Total Liabilities stood at $36.3 million for FY2024, which was up 429.03% from $6.9 million recorded in FY2023.
  • Corvus Pharmaceuticals' Total Liabilities' 5-year high stood at $36.3 million during FY2024, with a 5-year trough of $6.9 million in FY2023.
  • For the 3-year period, Corvus Pharmaceuticals' Total Liabilities averaged around $18.4 million, with its median value being $12.1 million (2022).
  • In the last 5 years, Corvus Pharmaceuticals' Total Liabilities slumped by 43.35% in 2023 and then skyrocketed by 429.03% in 2024.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Total Liabilities stood at $12.1 million in 2022, then crashed by 43.35% to $6.9 million in 2023, then skyrocketed by 429.03% to $36.3 million in 2024.